ENSG vs TAK
Ensign Group vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | ENSG | TAK |
|---|
| AI Score |
69
|
67
|
| Price |
$180.10
|
$17.49
|
| P/E Ratio |
27.43×
|
48.87×
|
| ROE |
15.4%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
62.1%
|
| Debt / Equity |
0.92×
|
0.65×
|
| Dividend Yield |
0.1%
|
3.6%
|
| RSI (14) |
71.8
|
61.6
|
| Beta |
0.694
|
0.088
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus TAK.
ENSG leads by 2 points.
ENSG scores 69/100 (Buy) versus TAK at 67/100 (Insufficient Data).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical